Clinical Scorecard: Exploring the Role of Adipose Tissue in Sex Steroid Dynamics Among Postmenopausal Women Undergoing Hormone Therapy

At a Glance

Key Highlights

• Adipose tissue acts as an active endocrine organ with higher local concentrations of sex steroids than circulating levels.
• Menopausal hormone therapy increases estrogen concentrations and estrogen-to-androgen ratios in both subcutaneous and visceral adipose tissue.
• MHT may mitigate menopause-associated central adiposity and related cardiometabolic risks by altering local sex steroid metabolism.

Guideline-Based Recommendations

Diagnosis

• Assess body fat distribution changes in postmenopausal women, focusing on visceral versus subcutaneous adiposity.
• Evaluate circulating and local adipose tissue sex steroid concentrations when investigating menopausal metabolic changes.

Management

• Consider menopausal hormone therapy to potentially improve estrogen-to-androgen balance in adipose tissue and reduce central adiposity.
• Tailor MHT dosing to optimize local estrogen effects in adipose tissue, acknowledging dose-dependent changes in visceral fat steroid ratios.

Monitoring & Follow-up

• Monitor changes in body composition, including visceral and subcutaneous fat distribution, during MHT.
• Evaluate cardiometabolic parameters such as insulin resistance, lipid profile, and blood pressure in postmenopausal women on MHT.

Risks

• Be cautious interpreting gene expression data on steroid metabolism enzymes due to limited sample sizes and variability.
• Recognize that long-term effects of MHT on local steroid metabolism and body composition require further longitudinal study.

Patient & Prescribing Data

Postmenopausal women receiving oral menopausal hormone therapy

Oral MHT increases estrogen levels and estrogen-to-androgen ratios in adipose tissue, potentially favoring a healthier fat distribution and reducing metabolic risk.

Clinical Best Practices

• Incorporate assessment of adipose tissue distribution and local sex steroid metabolism in managing postmenopausal women.
• Use MHT judiciously to target improvements in local estrogen activity within adipose tissue, considering individual patient factors such as obesity and time since menopause.
• Encourage further research and longitudinal monitoring to clarify MHT’s impact on muscle steroid metabolism and overall body composition.

References

• Hetemäki et al., Study on MHT and adipose tissue sex steroids
• Review on adipose tissue as an endocrine organ
• Menopause and central adiposity cardiovascular risk
• Steroid sulfatase role in estrogen metabolism
• Sex-steroid intracrinology in postmenopause